《2025首尔共识:肠易激综合征临床实践指南》解读

Interpretation on the 2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome

  • 摘要: 韩国胃肠病学会及韩国神经胃肠病学与动力学会于2025年发布了《2025首尔共识:肠易激综合征临床实践指南》,该共识基于GRADE方法学框架对证据质量和推荐强度进行分级,围绕肠易激综合征(irritable bowel syndrome, IBS)的定义与分型、诊断策略、生活方式干预、药物治疗及心理疗法等核心问题,制定了22条推荐意见。主要内容包括:确立IBS的积极诊断策略;提出低可发酵寡糖、二糖、单糖及多元醇饮食管理及运动干预等生活方式干预方案;细化便秘型与腹泻型IBS的药物治疗选择,重点涉及促泌剂、 5-羟色胺3受体拮抗剂、 5-羟色胺4受体激动剂、利福昔明及神经调节剂等药物的应用;将胃肠道导向心理疗法纳入难治性IBS的干预策略。本文基于上述内容对该共识进行解读,并与国内外权威共识进行比较,以期为我国临床医师精准诊治与长期管理IBS提供参考。需要指出的是,该共识的循证证据主要来源于韩国及欧美人群,缺乏中国本土高质量临床研究支持,其推荐意见在我国人群中的适用性仍有待进一步验证。因此,临床实践中应结合我国患者特点及本土证据审慎、合理应用。

     

    Abstract: In 2025, the Korean Society of Neurogastroenterology and Motility published the 2025 Seoul Consensus on Clinical Practice Guidelines for Irritable Bowel Syndrome. Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to rate the quality of evidence and strength of recommendations, the consensus developed 22 recommendations covering the definition and subtypes, diagnostic strategies, lifestyle interventions, pharmacological treatment, and psychological therapies for irritable bowel syndrome (IBS). Its principal recommendations include:adopting a positive diagnostic strategy for IBS; implementing lifestyle interventions, including a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs), as well as appropriate physical activity; refining pharmacological treatment options for IBS with predominant constipation and IBS with predominant diarrhea, particularly the use of secretagogues, serotonin type 3 receptor antagonists, serotonin type 4 receptor agonists, rifaximin, and neuromodulators; and incorporating gut-directed psychological therapies into the management of refractory IBS. This article interprets these recommendations and compares them with authoritative Chinese and international consensuses and guidelines, aiming to inform the precise diagnosis, individualized treatment, and long-term management of IBS in China. Notably, most evidence underpinning the consensus was derived from Korean, European, and North American populations, with limited support from high-quality clinical studies conducted in China. The applicability of these recommendations to Chinese patients therefore requires further validation. In clinical practice, the recommendations should be applied prudently in consideration of the characteristics of Chinese patients and locally generated evidence.

     

/

返回文章
返回